• Phase II, open-label study to assess the safety and immunogenicity of Fluzone® High-Dose Quadrivalent (Influenza Vaccine), 2021–2022 Formulation and a third dose of mRNA-1273 COVID-19 vaccine (Moderna) administered either concomitantly or singly in adults 65 years of age and older previously vaccinated with a 2-dose schedule of mRNA-1273 vaccine Cite CITE Title : Phase II, open-label study to assess the safety and immunogenicity of Fluzone® High-Dose Quadrivalent (Influenza Vaccine), 2021–2022 Formulation and a third dose of mRNA-1273 COVID-19 vaccine (Moderna) administered either concomitantly or singly in adults 65 years of age and older previously vaccinated with a 2-dose schedule of mRNA-1273 vaccine Personal Author(s) : Izikson, Ruvim Corporate Authors(s) : Sanofi Pasteur. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 20, 2021 Series : ACIP meeting Influenza URL : https://stacks.cdc.gov/view/cdc/110912 Izikson, Ruvim (2021). Phase II, open-label study to assess the safety and immunogenicity of Fluzone® High-Dose Quadrivalent (Influenza Vaccine), 2021–2022 Formulation and a third dose of mRNA-1273 COVID-19 vaccine (Moderna) administered either concomitantly or singly in adults 65 years of age and older previously vaccinated with a 2-dose schedule of mRNA-1273 vaccine. 202113(120302). Izikson, Ruvim "Phase II, open-label study to assess the safety and immunogenicity of Fluzone® High-Dose Quadrivalent (Influenza Vaccine), 2021–2022 Formulation and a third dose of mRNA-1273 COVID-19 vaccine (Moderna) administered either concomitantly or singly in adults 65 years of age and older previously vaccinated with a 2-dose schedule of mRNA-1273 vaccine" 202113, no. 120302 (2021) Izikson, Ruvim "Phase II, open-label study to assess the safety and immunogenicity of Fluzone® High-Dose Quadrivalent (Influenza Vaccine), 2021–2022 Formulation and a third dose of mRNA-1273 COVID-19 vaccine (Moderna) administered either concomitantly or singly in adults 65 years of age and older previously vaccinated with a 2-dose schedule of mRNA-1273 vaccine" vol. 202113, no. 120302, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 749.57 KB] Personal Author: Izikson, Ruvim October 20, 2021 | ACIP meeting Influenza Description: 02-influenza-izikson-508.pdf File Type: [PDF - 749.57 KB] File Type: [PDF - 749.57 KB] WG interpretation of the EtR regarding use of RZV in immunocompromised adults, considerations for use, and proposed policy options Cite CITE Title : WG interpretation of the EtR regarding use of RZV in immunocompromised adults, considerations for use, and proposed policy options Personal Author(s) : Anderson, Tara Corporate Authors(s) : United States. Advisory Committee on Immunization Practices. Herpes Zoster Work Group. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 20, 2021 Series : ACIP meeting Herpes Zoster Vaccine URL : https://stacks.cdc.gov/view/cdc/110910 Anderson, Tara (2021). WG interpretation of the EtR regarding use of RZV in immunocompromised adults, considerations for use, and proposed policy options. 202113(120202). Anderson, Tara "WG interpretation of the EtR regarding use of RZV in immunocompromised adults, considerations for use, and proposed policy options" 202113, no. 120202 (2021) Anderson, Tara "WG interpretation of the EtR regarding use of RZV in immunocompromised adults, considerations for use, and proposed policy options" vol. 202113, no. 120202, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 1.24 MB] Personal Author: Anderson, Tara October 20, 2021 | ACIP meeting Herpes Zoster Vaccine Description: 02-ZosterVaccines-Anderson-508.pdf File Type: [PDF - 1.24 MB] File Type: [PDF - 1.24 MB] Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options Cite CITE Title : Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options Personal Author(s) : Kobayashi, Miwako Corporate Authors(s) : National Center for Immunization and Respiratory Diseases (U.S.) Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 20, 2021 Series : ACIP meeting Pneumococcal Vaccines URL : https://stacks.cdc.gov/view/cdc/110908 Kobayashi, Miwako (2021). Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options. 202113(120102). Kobayashi, Miwako "Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options" 202113, no. 120102 (2021) Kobayashi, Miwako "Considerations for age-based and risk-based use of PCV15 and PCV20 among U.S. adults and proposed policy options" vol. 202113, no. 120102, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 746.53 KB] Personal Author: Kobayashi, Miwako October 20, 2021 | ACIP meeting Pneumococcal Vaccines Description: 02-Pneumococcal-Kobayashi-508.pdf File Type: [PDF - 746.53 KB] File Type: [PDF - 746.53 KB] ACIP COVID-19 Vaccines Work Group Cite CITE Title : ACIP COVID-19 Vaccines Work Group Personal Author(s) : Daley, Matthew F. Corporate Authors(s) : United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 21, 2021 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/110914 Daley, Matthew F. (2021). ACIP COVID-19 Vaccines Work Group. 202113(120202). Daley, Matthew F. "ACIP COVID-19 Vaccines Work Group" 202113, no. 120202 (2021) Daley, Matthew F. "ACIP COVID-19 Vaccines Work Group" vol. 202113, no. 120202, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 989.75 KB] Personal Author: Daley, Matthew F. October 21, 2021 | ACIP meeting COVID-19 Vaccines Description: slides-2021-10-20-21/01-COVID-Daley-508.pdf File Type: [PDF - 989.75 KB] File Type: [PDF - 989.75 KB] Pneumococcal vaccines Cite CITE Title : Pneumococcal vaccines Personal Author(s) : Poehling, Katherine A. Corporate Authors(s) : United States. Advisory Committee on Immunization Practices. Pneumococcal Vaccines Work Group. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 20, 2021 Series : ACIP meeting Pneumococcal Vaccines URL : https://stacks.cdc.gov/view/cdc/110907 Poehling, Katherine A. (2021). Pneumococcal vaccines. 202113(120101). Poehling, Katherine A. "Pneumococcal vaccines" 202113, no. 120101 (2021) Poehling, Katherine A. "Pneumococcal vaccines" vol. 202113, no. 120101, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 157.70 KB] Personal Author: Poehling, Katherine A. October 20, 2021 | ACIP meeting Pneumococcal Vaccines Description: 01-Pneumococcal-Poehling-508.pdf File Type: [PDF - 157.70 KB] File Type: [PDF - 157.70 KB] Change in age indication for Flucelvax quadrivalent Cite CITE Title : Change in age indication for Flucelvax quadrivalent Personal Author(s) : Grohskopf, Lisa A. Corporate Authors(s) : National Center for Immunization and Respiratory Diseases (U.S.). Influenza Division. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 20, 2021 Series : ACIP meeting Influenza URL : https://stacks.cdc.gov/view/cdc/110913 Grohskopf, Lisa A. (2021). Change in age indication for Flucelvax quadrivalent. 202113(120303). Grohskopf, Lisa A. "Change in age indication for Flucelvax quadrivalent" 202113, no. 120303 (2021) Grohskopf, Lisa A. "Change in age indication for Flucelvax quadrivalent" vol. 202113, no. 120303, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 267.13 KB] Personal Author: Grohskopf, Lisa A. October 20, 2021 | ACIP meeting Influenza Description: 03-influenza-grohskopf-508.pdf File Type: [PDF - 267.13 KB] File Type: [PDF - 267.13 KB] Seasonal influenza vaccines Cite CITE Title : Seasonal influenza vaccines Personal Author(s) : Talbot, H. Keipp Corporate Authors(s) : United States. Advisory Committee on Immunization Practices. Influenza Work Group. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 20, 2021 Series : ACIP meeting Influenza URL : https://stacks.cdc.gov/view/cdc/110911 Talbot, H. Keipp (2021). Seasonal influenza vaccines. 202113(120301). Talbot, H. Keipp "Seasonal influenza vaccines" 202113, no. 120301 (2021) Talbot, H. Keipp "Seasonal influenza vaccines" vol. 202113, no. 120301, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 156.66 KB] Personal Author: Talbot, H. Keipp October 20, 2021 | ACIP meeting Influenza Description: 01-influenza-talbot-508.pdf File Type: [PDF - 156.66 KB] File Type: [PDF - 156.66 KB] COVID-19 vaccine effectiveness for Moderna and Janssen vaccines Cite CITE Title : COVID-19 vaccine effectiveness for Moderna and Janssen vaccines Personal Author(s) : Jones, Jefferson Corporate Authors(s) : CDC COVID-19 Response. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 21, 2021 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/110923 Jones, Jefferson (2021). COVID-19 vaccine effectiveness for Moderna and Janssen vaccines. 202113(120211). Jones, Jefferson "COVID-19 vaccine effectiveness for Moderna and Janssen vaccines" 202113, no. 120211 (2021) Jones, Jefferson "COVID-19 vaccine effectiveness for Moderna and Janssen vaccines" vol. 202113, no. 120211, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 4.32 MB] Personal Author: Jones, Jefferson October 21, 2021 | ACIP meeting COVID-19 Vaccines Description: 10-COVID-jones-508.pdf File Type: [PDF - 4.32 MB] File Type: [PDF - 4.32 MB] Evidence to recommendation framework : Moderna & Janssen COVID-19 vaccine booster dose Cite CITE Title : Evidence to recommendation framework : Moderna & Janssen COVID-19 vaccine booster dose Personal Author(s) : Dooling, Kathleen Corporate Authors(s) : United States. Advisory Committee on Immunization Practices. COVID-19 Vaccines Work Group. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 21, 2021 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/110924 Dooling, Kathleen (2021). Evidence to recommendation framework : Moderna & Janssen COVID-19 vaccine booster dose. 202113(120212). Dooling, Kathleen "Evidence to recommendation framework : Moderna & Janssen COVID-19 vaccine booster dose" 202113, no. 120212 (2021) Dooling, Kathleen "Evidence to recommendation framework : Moderna & Janssen COVID-19 vaccine booster dose" vol. 202113, no. 120212, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 3.23 MB] Personal Author: Dooling, Kathleen October 21, 2021 | ACIP meeting COVID-19 Vaccines Description: 11-COVID-Dooling-508.pdf File Type: [PDF - 3.23 MB] File Type: [PDF - 3.23 MB] Early safety monitoring for additional COVID-19 vaccine doses : reports to VAERS and v-safe Cite CITE Title : Early safety monitoring for additional COVID-19 vaccine doses : reports to VAERS and v-safe Personal Author(s) : Hause, Anne M. Corporate Authors(s) : CDC COVID-19 Vaccine Task Force. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 21, 2021 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/110918 Hause, Anne M. (2021). Early safety monitoring for additional COVID-19 vaccine doses : reports to VAERS and v-safe. 202113(120206). Hause, Anne M. "Early safety monitoring for additional COVID-19 vaccine doses : reports to VAERS and v-safe" 202113, no. 120206 (2021) Hause, Anne M. "Early safety monitoring for additional COVID-19 vaccine doses : reports to VAERS and v-safe" vol. 202113, no. 120206, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 707.41 KB] Personal Author: Hause, Anne M. October 21, 2021 | ACIP meeting COVID-19 Vaccines Description: 05-COVID-Hause-508.pdf File Type: [PDF - 707.41 KB] File Type: [PDF - 707.41 KB] Booster dose of Janssen COVID-19 Vaccine (Ad26.COV2.S) following primary vaccination Cite CITE Title : Booster dose of Janssen COVID-19 Vaccine (Ad26.COV2.S) following primary vaccination Personal Author(s) : Heaton, Penny M.;Douoguih, Macaya; Corporate Authors(s) : Janssen Pharmaceuticals Companies of Johnson & Johnson. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 21, 2021 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/110916 Heaton, Penny M. and Douoguih, Macaya (2021). Booster dose of Janssen COVID-19 Vaccine (Ad26.COV2.S) following primary vaccination. 202113(120204). Heaton, Penny M. and Douoguih, Macaya "Booster dose of Janssen COVID-19 Vaccine (Ad26.COV2.S) following primary vaccination" 202113, no. 120204 (2021) Heaton, Penny M. and Douoguih, Macaya "Booster dose of Janssen COVID-19 Vaccine (Ad26.COV2.S) following primary vaccination" vol. 202113, no. 120204, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 1.13 MB] Personal Author: Heaton, Penny M. ; Douoguih, Macaya October 21, 2021 | ACIP meeting COVID-19 Vaccines Description: 03-COVID-Heaton-Douoguih-508.pdf File Type: [PDF - 1.13 MB] File Type: [PDF - 1.13 MB] Myopericarditis following COVID-19 vaccination : updates from the Vaccine Adverse Event Reporting System (VAERS) Cite CITE Title : Myopericarditis following COVID-19 vaccination : updates from the Vaccine Adverse Event Reporting System (VAERS) Personal Author(s) : Su, John R. Corporate Authors(s) : CDC COVID-19 Vaccine Task Force. Vaccine Safety Team. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 21, 2021 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/110920 Su, John R. (2021). Myopericarditis following COVID-19 vaccination : updates from the Vaccine Adverse Event Reporting System (VAERS). 202113(120208). Su, John R. "Myopericarditis following COVID-19 vaccination : updates from the Vaccine Adverse Event Reporting System (VAERS)" 202113, no. 120208 (2021) Su, John R. "Myopericarditis following COVID-19 vaccination : updates from the Vaccine Adverse Event Reporting System (VAERS)" vol. 202113, no. 120208, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 780.22 KB] Personal Author: Su, John R. October 21, 2021 | ACIP meeting COVID-19 Vaccines Description: 07-COVID-Su-508.pdf File Type: [PDF - 780.22 KB] File Type: [PDF - 780.22 KB] Safety and immunogenicity of a 50 µg booster dose of Moderna COVID-19 vaccine Cite CITE Title : Safety and immunogenicity of a 50 µg booster dose of Moderna COVID-19 vaccine Personal Author(s) : Miller, Jacqueline M. Corporate Authors(s) : Moderna (firm) Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 21, 2021 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/110915 Miller, Jacqueline M. (2021). Safety and immunogenicity of a 50 µg booster dose of Moderna COVID-19 vaccine. 202113(120203). Miller, Jacqueline M. "Safety and immunogenicity of a 50 µg booster dose of Moderna COVID-19 vaccine" 202113, no. 120203 (2021) Miller, Jacqueline M. "Safety and immunogenicity of a 50 µg booster dose of Moderna COVID-19 vaccine" vol. 202113, no. 120203, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 901.35 KB] Personal Author: Miller, Jacqueline M. October 21, 2021 | ACIP meeting COVID-19 Vaccines Description: 02-COVID-Miller-508.pdf File Type: [PDF - 901.35 KB] File Type: [PDF - 901.35 KB] COVID-19 Vaccine Safety Technical (VaST) Work Group Cite CITE Title : COVID-19 Vaccine Safety Technical (VaST) Work Group Personal Author(s) : Talbot, H. Keipp;Hopkins, Robert H.; Corporate Authors(s) : COVID-19 Vaccine Safety Technical (VaST) Work Group. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 21, 2021 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/110922 Talbot, H. Keipp and Hopkins, Robert H. (2021). COVID-19 Vaccine Safety Technical (VaST) Work Group. 202113(120210). Talbot, H. Keipp and Hopkins, Robert H. "COVID-19 Vaccine Safety Technical (VaST) Work Group" 202113, no. 120210 (2021) Talbot, H. Keipp and Hopkins, Robert H. "COVID-19 Vaccine Safety Technical (VaST) Work Group" vol. 202113, no. 120210, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 299.24 KB] Personal Author: Talbot, H. Keipp ; Hopkins, Robert H. October 21, 2021 | ACIP meeting COVID-19 Vaccines Description: 09-COVID-Talbot-508.pdf File Type: [PDF - 299.24 KB] File Type: [PDF - 299.24 KB] DMID 21-0012 - heterologous platform boost study : mix and match Cite CITE Title : DMID 21-0012 - heterologous platform boost study : mix and match Personal Author(s) : Atmar, Robert L. Corporate Authors(s) : Baylor College of Medicine. Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 21, 2021 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/110917 Atmar, Robert L. (2021). DMID 21-0012 - heterologous platform boost study : mix and match. 202113(120205). Atmar, Robert L. "DMID 21-0012 - heterologous platform boost study : mix and match" 202113, no. 120205 (2021) Atmar, Robert L. "DMID 21-0012 - heterologous platform boost study : mix and match" vol. 202113, no. 120205, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 1.45 MB] Personal Author: Atmar, Robert L. October 21, 2021 | ACIP meeting COVID-19 Vaccines Description: 04-COVID-Atmar-508.pdf File Type: [PDF - 1.45 MB] File Type: [PDF - 1.45 MB] Myocarditis analyses in the Vaccine Safety Datalink : rapid cycle analyses and “head-to-head” product comparisons Cite CITE Title : Myocarditis analyses in the Vaccine Safety Datalink : rapid cycle analyses and “head-to-head” product comparisons Personal Author(s) : Klein, Nicola P. Corporate Authors(s) : Kaiser Permanente Vaccine Study Center.;Marshfield Clinic Research Institute. Vaccine Safety Datalink. Immunization Safety Office.; Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 21, 2021 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/110921 Klein, Nicola P. (2021). Myocarditis analyses in the Vaccine Safety Datalink : rapid cycle analyses and “head-to-head” product comparisons. 202113(120209). Klein, Nicola P. "Myocarditis analyses in the Vaccine Safety Datalink : rapid cycle analyses and “head-to-head” product comparisons" 202113, no. 120209 (2021) Klein, Nicola P. "Myocarditis analyses in the Vaccine Safety Datalink : rapid cycle analyses and “head-to-head” product comparisons" vol. 202113, no. 120209, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 567.66 KB] Personal Author: Klein, Nicola P. October 21, 2021 | ACIP meeting COVID-19 Vaccines Description: 08-COVID-Klein-508.pdf File Type: [PDF - 567.66 KB] File Type: [PDF - 567.66 KB] Interim clinical considerations for Moderna and Janssen COVID-19 vaccine booster doses Cite CITE Title : Interim clinical considerations for Moderna and Janssen COVID-19 vaccine booster doses Personal Author(s) : Reddy, Sujan Conference Author(s) : United States. Advisory Committee on Immunization Practices. Meeting (2021 Oct 20-21 : Atlanta, GA) Published Date : October 21, 2021 Series : ACIP meeting COVID-19 Vaccines URL : https://stacks.cdc.gov/view/cdc/110925 Reddy, Sujan (2021). Interim clinical considerations for Moderna and Janssen COVID-19 vaccine booster doses. 202113(120213). Reddy, Sujan "Interim clinical considerations for Moderna and Janssen COVID-19 vaccine booster doses" 202113, no. 120213 (2021) Reddy, Sujan "Interim clinical considerations for Moderna and Janssen COVID-19 vaccine booster doses" vol. 202113, no. 120213, 2021 Export RIS Citation Information. Copy Copied Save Generic APA MLA Chicago RIS [PDF - 527.99 KB] Personal Author: Reddy, Sujan October 21, 2021 | ACIP meeting COVID-19 Vaccines Description: 12-COVID-Reddy-508.pdf File Type: [PDF - 527.99 KB] File Type: [PDF - 527.99 KB]

More +